Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as triamcinolone acetonide (Triesence®), TA, Triesence, corticosteroid, suprachoroidal CLS-TA
triamcinolone acetonide · 1 trial · 5 indications
Intraocular pressure is the fluid pressure inside the eye. Intraocular pressure change from baseline at week 8 was measured by Goldmann applanation tonometry. Tonometry is the method eye care professionals use to determine this pressure. Intraocular pressure is typically measured in millimeters of mercury. A higher pressure inside the eye can be a risk factor for developing glaucoma or glaucoma progression leading to optic nerve damage. A negative change indicates a reduction in intraocular pressure.
Visual acuity (VA) rates a person's ability to recognize small details with precision. Best corrected VA refers to this measurement when the best vision has be achieved following refraction. Visual acuity change from baseline at 8 and 26 weeks was measured following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol using standardized lighting and lanes and an ETDRS eye chart. This eye chart comprises rows of letters, with 5 letters per row, and with the letter size from line to line varying logarithmically and is used to estimate visual acuity. Visual acuity is scored with reference to the logarithm of the minimum angle of resolution or logMAR. Zero logMAR indicates standard vision, positive values indicate poor vision and negative values indicate good vision. A negative changes indicates an improvement in visual acuity.
| Arm | Type | Description |
|---|---|---|
| triamcinolone acetonide (Triesence®) | EXPERIMENTAL | TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS) |
| Name | Type | Description |
|---|---|---|
| triamcinolone acetonide (Triesence®) | DRUG | 4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space |
Inclusion Criteria: * diagnosis of non-infectious intermediate, posterior or pan-uveitis Exclusion Criteria: * any ocular trauma within the past 6 months in the study eye * any injection of intraocular corticosteroids or steroid implant or the Ozurdex® implant in the 6 months prior to the study t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Roivant Sciences Ltd. | ROIV | 1 | PHASE3 | Brepocitinib |
| Eli Lilly and Company | LLY | 1 | PHASE3 | Baricitinib |
| ANI Pharmaceuticals, Inc. | ANIP | 1 | PHASE3 | Yutiq |
Triamcinolone acetonide is being developed by Clearside Biomedical for the treatment of uveitis, including intermediate uveitis, posterior uveitis, panuveitis, and noninfectious uveitis. It is a small molecule corticosteroid delivered via suprachoroidal injection using a microneedle, and it is currently in Phase 1 clinical development.
Triamcinolone acetonide targets NR3C1, the glucocorticoid receptor, and acts as an agonist at this receptor. By activating NR3C1, it produces anti-inflammatory effects relevant to treating uveitis, an inflammatory eye condition. This mechanism underlies its development as a corticosteroid therapy for noninfectious uveitis.
Clearside Biomedical, Inc. (ticker: CLSD) is developing triamcinolone acetonide for uveitis. The company is advancing the asset through clinical development, with a focus on suprachoroidal delivery via microneedle. Clearside Biomedical is the sponsor of the Phase 1 study evaluating this formulation.
Triamcinolone acetonide is in Phase 1 clinical development for uveitis. It is an investigational therapy and has not been approved for this indication. The Phase 1 program has completed, and the drug remains in clinical development under Clearside Biomedical.
Triamcinolone acetonide has been evaluated in one completed Phase 1 trial, NCT01789320, titled "Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis." The study enrolled 11 participants in the United States and included patients with intermediate uveitis, posterior uveitis, panuveitis, and noninfectious uveitis.
Triamcinolone acetonide is also known as triamcinolone acetonide (Triesence). Triesence is a brand name for the same active ingredient, triamcinolone acetonide. Clearside Biomedical is developing this corticosteroid for uveitis using suprachoroidal delivery via microneedle.